Dana B. Cardin

5.0k total citations
67 papers, 1.2k citations indexed

About

Dana B. Cardin is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dana B. Cardin has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 27 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dana B. Cardin's work include Pancreatic and Hepatic Oncology Research (35 papers), Colorectal Cancer Treatments and Studies (22 papers) and Cancer Genomics and Diagnostics (22 papers). Dana B. Cardin is often cited by papers focused on Pancreatic and Hepatic Oncology Research (35 papers), Colorectal Cancer Treatments and Studies (22 papers) and Cancer Genomics and Diagnostics (22 papers). Dana B. Cardin collaborates with scholars based in United States, Spain and Australia. Dana B. Cardin's co-authors include Jordan Berlin, Laura W. Goff, Heinz‐Josef Lenz, Efrat Dotan, Emily Castellanos, Andrea Wang‐Gillam, Satya Das, Wells A. Messersmith, Steven J. Cohen and Ann M. Kapoun and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Dana B. Cardin

64 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dana B. Cardin United States	19	820	406	264	199	188	67	1.2k
Maristella Bianconi Italy	20	558 0.7×	416 1.0×	402 1.5×	375 1.9×	110 0.6×	59	1.2k
Ingrid Garajová Italy	19	503 0.6×	404 1.0×	359 1.4×	218 1.1×	104 0.6×	82	1.0k
Heinz‐Josef Lenz United States	14	668 0.8×	420 1.0×	239 0.9×	210 1.1×	213 1.1×	26	1.2k
Alessandro Bittoni Italy	23	935 1.1×	437 1.1×	479 1.8×	488 2.5×	158 0.8×	93	1.5k
Anwaar Saeed United States	18	964 1.2×	280 0.7×	198 0.8×	365 1.8×	186 1.0×	167	1.4k
Nigel C. Bird United Kingdom	17	467 0.6×	373 0.9×	257 1.0×	150 0.8×	85 0.5×	28	1.1k
Farhat Ben Ayed Tunisia	17	594 0.7×	385 0.9×	382 1.4×	163 0.8×	170 0.9×	54	1.2k
Pilar Alfonso Spain	22	641 0.8×	435 1.1×	97 0.4×	271 1.4×	140 0.7×	115	1.7k
Satoru Moriyama Japan	24	574 0.7×	929 2.3×	245 0.9×	486 2.4×	119 0.6×	82	1.7k
Shu Zhao China	21	785 1.0×	490 1.2×	409 1.5×	337 1.7×	134 0.7×	43	1.4k

Countries citing papers authored by Dana B. Cardin

Since Specialization

Citations

This map shows the geographic impact of Dana B. Cardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana B. Cardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana B. Cardin more than expected).

Fields of papers citing papers by Dana B. Cardin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana B. Cardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana B. Cardin. The network helps show where Dana B. Cardin may publish in the future.

Co-authorship network of co-authors of Dana B. Cardin

This figure shows the co-authorship network connecting the top 25 collaborators of Dana B. Cardin. A scholar is included among the top collaborators of Dana B. Cardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana B. Cardin. Dana B. Cardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamid, Omid, Dana B. Cardin, F. Stephen Hodi, et al.. (2025). First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 31(19). 4089–4100.

Ciombor, Kristen K., Jennifer G. Whisenant, Gregory D. Ayers, et al.. (2025). Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer. Clinical Cancer Research. 31(8). 1437–1448. 6 indexed citations

Ciombor, Kristen K., Jennifer G. Whisenant, Gregory D. Ayers, et al.. (2023). P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer. Annals of Oncology. 34. S82–S82. 1 indexed citations

Das, Satya, Aman Chauhan, Liping Du, et al.. (2022). External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Network Open. 5(1). e2144170–e2144170. 12 indexed citations

Cann, Christopher, Brian C. Grieb, Kristen K. Ciombor, et al.. (2022). Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 40(16_suppl). 3559–3559.

Cohen, Allison S., Gary T. Smith, Todd E. Peterson, et al.. (2021). First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer. Journal of Nuclear Medicine. 63(1). 36–43. 20 indexed citations

Lenz, Heinz‐Josef, Sara Lonardi, Vittorina Zagonel, et al.. (2021). Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. Journal of Clinical Oncology. 39(3_suppl). 58–58. 14 indexed citations

Kim, Joseph W., Dana B. Cardin, Ulka N. Vaishampayan, et al.. (2021). Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist. 26(7). e1104–e1109. 10 indexed citations

Das, Satya, Liping Du, Shikha Jain, et al.. (2021). A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.. Journal of Clinical Oncology. 39(3_suppl). 363–363. 1 indexed citations

10.

Wu, Christina, Terence M. Williams, Ryan Robb, et al.. (2020). Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical Cancer Research. 26(13). 3117–3125. 13 indexed citations

11.

Varghese, Anna M., Dana B. Cardin, Al B. Benson, et al.. (2020). Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clinical Cancer Research. 26(7). 1555–1562. 13 indexed citations

12.

Dotan, Efrat, Dana B. Cardin, Heinz‐Josef Lenz, et al.. (2020). Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clinical Cancer Research. 26(20). 5348–5357. 59 indexed citations

13.

Das, Satya & Dana B. Cardin. (2020). Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. Current Treatment Options in Oncology. 21(8). 62–62. 6 indexed citations

14.

Lenz, Heinz‐Josef, Eric Van Cutsem, María Luisa Limón, et al.. (2018). Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii714–viii714. 68 indexed citations

15.

Thota, Ramya, Raul S. González, Jordan Berlin, Dana B. Cardin, & Chanjuan Shi. (2017). Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?. American Journal of Clinical Pathology. 148(3). 208–214. 21 indexed citations

16.

Philip, Philip Agop, Jill Lacy, Scot Dowden, et al.. (2016). LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology. 34(4_suppl). TPS477–TPS477. 3 indexed citations

17.

Chan, Emily, Lori R. Arlinghaus, Dana B. Cardin, et al.. (2016). Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology. 119(2). 312–318. 59 indexed citations

18.

Tempero, Margaret A., Dana B. Cardin, Andrew V. Biankin, et al.. (2015). Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT). Gastroenterology. 148(4). S–944. 1 indexed citations

19.

Goff, Laura W., Nilay Thakkar, Liping Du, et al.. (2014). Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. PLoS ONE. 9(9). e107424–e107424. 80 indexed citations

20.

Ciombor, Kristen K., Dana B. Cardin, Emily Chan, et al.. (2012). Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer.. Journal of Clinical Oncology. 30(15_suppl). e14503–e14503. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact